On March 1, 2026 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, reported that South Korea’s National Health Insurance Service (NHIS) has approved the reimbursement of XPOVIO (selinexor) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma (MM) after one prior therapy. The reimbursement has taken effect on March 1, 2026. This marks the second XPOVIO indication to be approved for reimbursement in South Korea.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As Antengene continues to expand its footprint across the Asia Pacific region, the Company remains committed to improving patient access to its innovative therapies. To date, XPOVIO has been approved in South Korea for three indications in MM and diffuse large B-cell lymphoma (DLBCL), both major hematological malignancies. Two of these indications have been approved for reimbursement, including XPOVIO in combination with dexamethasone for the treatment of adult patients with relapsed or refractory MM (R/R MM) who have received at least four prior therapies, as well as the newly reimbursed indication. With expanded reimbursement coverage, XPOVIO is expected to benefit a broader patient population and further contribute to the management of hematological malignancies in South Korea.
With a novel mechanism of action, XPOVIO is the world’s first approved orally-available, selective XPO1 inhibitor. XPOVIO has already been approved in ten countries and regions in APAC, and has been included in the national insurance schemes in five of these markets (the mainland of China, Taiwan market, Australia, Singapore and South Korea). Moving forward, Antengene will continue to pursue broader access for XPOVIO across APAC markets.
(Press release, Antengene, MAR 1, 2026, View Source [SID1234663147])